Purpura, Thrombocytopenic, Idiopathic

6
Pipeline Programs
6
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
2
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 5 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Rigel Pharmaceuticals
Rigel PharmaceuticalsSOUTH SAN FRANCISCO, CA
1 program
1
Fostamatinib Disodium / R935788Phase 21 trial
Active Trials
NCT00706342CompletedEst. Apr 2010
Grifols
GrifolsNEW YORK, NY
1 program
1
Immune Globulin IV [Human], 10% Caprylate/Chromatography PurifiedPhase 21 trial
Active Trials
NCT00220727CompletedEst. Oct 2003
GS
Gilead SciencesFOSTER CITY, CA
2 programs
2
veltuzumabPhase 1/2Monoclonal Antibody1 trial
veltuzumabPhase 1/2Monoclonal Antibody
Active Trials
NCT00547066Terminated48Est. Nov 2011
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
BI 655064Phase 11 trial
Active Trials
NCT02009761Terminated6Est. Apr 2016
E
EisaiChina - Liaoning
1 program
1
E5501 40 mg 2 x 20-mg tablets, orally, fastedPhase 11 trial
Active Trials
NCT01327872Completed84Est. Jun 2011
Roche
RocheSTAVANGER NORWAY, Norway
1 program
The ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.N/A1 trial
Active Trials
NCT01101295Unknown250Est. Apr 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Rigel PharmaceuticalsFostamatinib Disodium / R935788
GrifolsImmune Globulin IV [Human], 10% Caprylate/Chromatography Purified
Gilead Sciencesveltuzumab
Boehringer IngelheimBI 655064
EisaiE5501 40 mg 2 x 20-mg tablets, orally, fasted
RocheThe ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.

Clinical Trials (6)

Total enrollment: 388 patients across 6 trials

NCT00706342Rigel PharmaceuticalsFostamatinib Disodium / R935788

Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)

Start: Jan 2007Est. completion: Apr 2010
Phase 2Completed
NCT00220727GrifolsImmune Globulin IV [Human], 10% Caprylate/Chromatography Purified

Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP

Start: Jul 2003Est. completion: Oct 2003
Phase 2Completed
NCT00547066Gilead Sciencesveltuzumab

Study of Veltuzumab (hA20) at Different Doses in Patients With ITP

Start: Nov 2007Est. completion: Nov 201148 patients
Phase 1/2Terminated
NCT02009761Boehringer IngelheimBI 655064

Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).

Start: Dec 2013Est. completion: Apr 20166 patients
Phase 1Terminated
NCT01327872EisaiE5501 40 mg 2 x 20-mg tablets, orally, fasted

Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects

Start: Feb 2011Est. completion: Jun 201184 patients
Phase 1Completed
NCT01101295RocheThe ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.

The ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.

Start: Apr 2010Est. completion: Apr 2017250 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 companies competing in this space